Corporate PresentationDownload July 2025 Presentation Select HighlightsJune 2, 2025News: STAT6 DC NominationView Press Release »May 18, 2025ATS Conference: STAT6 DataAccess Poster »May 8, 2025SID Conference: BTK DataAccess Poster » Latest Press ReleasesJuly 14, 2025Recludix Pharma Announces Strengthening of Leadership Team, Including Promotion of Dr. Brian Hodous to Chief Scientific OfficerRead More »June 2, 2025Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory Diseases and Achievement of Significant Milestone Under Collaboration with SanofiRead More »May 19, 2025Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma ModelRead More »May 7, 2025Recludix Pharma Presents Preclinical Data on First-in-Class BTK SH2 Domain Inhibitor Demonstrating Powerful BTK Inhibition, Exceptional Selectivity, and Encouraging Efficacy in a Model of Chronic Spontaneous UrticariaRead More » More Press Releases Events and PresentationsJune 30, 2025Recludix Platform has Unlocked Development of Oral, Reversible Small Molecule Inhibitors of SH2 DomainsView Poster »May 18, 2025Highly selective and reversible STAT6 inhibition demonstrates potential for differentiated efficacy and safety profile in type 2 allergic inflammationView Poster »May 8, 2025Novel Inhibitors of the BTK SH2 Domain Selectively and Potently Block BTK Signaling and are Efficacious in Preclinical Models of Chronic Spontaneous UrticariaView Poster »December 7, 2023STAT6 Program Highlighted in Sanofi R&D DayAccess Webcast » More Events and Presentations News Coverage HighlightsAugust 7, 2023BioCentury: Recludix: targeting STATs via their SH2 domainsRead More »July 20, 2023BioWorld: Recludix enters a potential $1.2B deal with SanofiRead More »July 20, 2023SCRIP: Sanofi Adds To Immunology Pipeline In Collaboration With Recludix Read More »July 20, 2023Fierce Biotech: Sanofi pays $125M to go after undruggable inflammatory target with Recludix’s preclinical programRead More »July 20, 2023Endpoints News: Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with RecludixRead More »
